Tuberculosis Vaccine Development: Progress in Clinical Evaluation | Zendy

Suraj B. Sable | Zendy; James E. Posey | Zendy; Thomas J. Scriba | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Tuberculosis Vaccine Development: Progress in Clinical Evaluation

Author(s) -

Suraj B. Sable,

James E. Posey,

Thomas J. Scriba

Publication year - 2019

Publication title -

clinical microbiology reviews

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 9.177

H-Index - 282

eISSN - 1070-6305

pISSN - 0893-8512

DOI - 10.1128/cmr.00100-19

Subject(s) - tuberculosis , tuberculosis vaccines , medicine , mycobacterium tuberculosis , bcg vaccine , immunology , clinical trial , disease , immunity , mycobacterium bovis , vaccination , vaccine efficacy , intensive care medicine , virology , immune system , pathology

Tuberculosis (TB) is the leading killer among all infectious diseases worldwide despite extensive use of theMycobacterium bovis bacille Calmette-Guérin (BCG) vaccine. A safer and more effective vaccine than BCG is urgently required. More than a dozen TB vaccine candidates are under active evaluation in clinical trials aimed to prevent infection, disease, and recurrence.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research